Pharmacoeconomic Analyses of Azathioprine, Methotrexate and Prospective Pharmacogenetic Testing for the Management of Inflammatory Bowel Disease
- 1 January 2006
- journal article
- Published by Springer Nature in PharmacoEconomics
- Vol. 24 (8) , 767-781
- https://doi.org/10.2165/00019053-200624080-00004
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- A Cost-Effectiveness Analysis of Alternative Disease Management Strategies in Patients with Crohn's Disease Treated with Azathioprine or 6-MercaptopurineAmerican Journal of Gastroenterology, 2005
- Two cases of thiopurine methyltransferase (TPMT) deficiency – a lucky save and a near miss with azathioprineBritish Journal of Clinical Pharmacology, 2005
- Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice?Pharmacogenetics and Genomics, 2005
- Cost‐effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2004
- General principles of medical therapy of inflammatory bowel diseaseGastroenterology Clinics of North America, 2004
- Methotrexate in inflammatory bowel diseaseGastroenterology Clinics of North America, 2004
- Mortality in inflammatory bowel disease: a population-based cohort studyGastroenterology, 2003
- Mistaken identityEuropean Journal of Gastroenterology & Hepatology, 2003
- Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in KoreaRheumatology, 2003
- Methotrexate in Crohn's disease: How is it doing?Gastroenterology, 1998